Elena Mazzotta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Elena Mazzotta has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Amedeo Bianchini
Post-Surgical and Transplant Intensive Care Unit, Department of Digestive, Hepatic and Endocrine-Metabolic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Giuseppe Massarenti, 9, 40138 Bologna, Italy
1 shared publication - Antonio Siniscalchi
Postoperative and Abdominal Organ Transplant Intensive Care Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
1 shared publication - Cecilia Modolon
Pediatric and Adult CardioThoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
1 shared publication - Chiara Elide Lizzio
Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
1 shared publication - Claudio Ricci
Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy
1 shared publication - Cristina Felicani
UOC Medicina ad Indirizzo Metabolico Nutrizionale, Policlinico di Modena, AOU Modena, Via del Pozzo, 71, 41125 Modena, Italy
1 shared publication
Latest Publications
- Open Access
- 28 March 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (7) , 870
Lung Ultrasound in Mechanical Ventilation: A Purposive Review
Background/Objectives: Lung ultrasound (LUS) has emerged as a crucial bedside tool for evaluating and managing patients with respiratory failure, particularly those receiving mechanical ventilation (MV). Its ability to rapidly characterise lung pathology, including extent, severity, and progression, has established LUS as a key diagnostic and monitoring modality in both hospital and home-care settings. Methods: This narrative review analyses the specific applications of LUS in the assessment and management of patients undergoing MV, aiming to optimise ventilatory strategies. Results: We examine the role of LUS in (1) identifying patients requiring MV; (2) guiding ventilator settings (Positive End Expiratory Pressure selection, inspiratory pressure adjustment, and patient-ventilator synchrony optimisation); (3) performing and monitoring recruitment manoeuvres; (4) assessing parenchymal damage and evaluating the response to medical and ventilatory therapies; (5) detecting ventilation-associated complications; (6) facilitating weaning from MV; and (7) assisting with airway management procedures, specifically tracheostomy. The utility of Transesophageal Lung Ultrasound (TELU) is also briefly discussed. Conclusions: This review highlights the potential of LUS to improve clinical decision making and patient outcomes in the context of MV.
- 28 March 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (7) , 870
Open AccessLung Ultrasound in Mechanical Ventilation: A Purposive Review
Background/Objectives: Lung ultrasound (LUS) has emerged as a crucial bedside tool for evaluating and managing patients with respiratory failure, particularly those receiving mechanical ventilation (MV). Its ability to rapidly characterise lung pathology, including extent, severity, and progression, has established LUS as a key diagnostic and monitoring modality in both hospital and home-care settings. Methods: This narrative review analyses the specific applications of LUS in the assessment and management of patients undergoing MV, aiming to optimise ventilatory strategies. Results: We examine the role of LUS in (1) identifying patients requiring MV; (2) guiding ventilator settings (Positive End Expiratory Pressure selection, inspiratory pressure adjustment, and patient-ventilator synchrony optimisation); (3) performing and monitoring recruitment manoeuvres; (4) assessing parenchymal damage and evaluating the response to medical and ventilatory therapies; (5) detecting ventilation-associated complications; (6) facilitating weaning from MV; and (7) assisting with airway management procedures, specifically tracheostomy. The utility of Transesophageal Lung Ultrasound (TELU) is also briefly discussed. Conclusions: This review highlights the potential of LUS to improve clinical decision making and patient outcomes in the context of MV.
- Open Access
- 8 November 2023
- Published by MDPI AG in Gastroenterology Insights
- Vol. 14 (4) , 553-563
COVID-19 and Acute Pancreatitis: Not Increased Risk but Reduced Care
Background and aim: Over the last few years, SARS-CoV-2 has been reported as a possible cause of acute pancreatitis (AP), but whether it is a relevant clinical–epidemiological entity is still a matter of debate. We aim to evaluate the epidemiological characteristics of AP during the first year of the COVID pandemic (2020) and compare them with the pre-COVID period (2008–2019) to identify any differences and clarify a potential causative role of SARS-CoV-2. Methods: We used a monocentric retrospective study of 132 AP patients during 2020 and 1987 AP patients during 2008–2019. Diagnosis and severity were classified according to the revised Atlanta criteria. Propensity score matching was performed according to clinical–epidemiological features, and outcome analysis was performed on two subgroups of 109 patients. Results: The total number of AP cases in 2020 is one of the lowest in the last 13 years (132 cases, median 161, IQR 146-183). No major epidemiological differences were noted. During 2020, we observed a significant modification of the distribution of etiologies (p < 0.001), mainly based on a decrease in biliary forms (59.6% vs. 43.2%) and an increase in alcoholic forms (6.9% vs. 12.9%). Idiopathic forms remain unchanged (20.5% vs. 21.9%). The proportion of AP of idiopathic etiology and SARS-CoV-2 infection was 0.008%. There were no differences in terms of severity distribution (p = 0.127), length of stay (p = 0.916), need for ICU (p = 0.139), or mortality (p = 0.462). Even among statistically matched groups, there were no differences between the length of stay (9 vs. 10 days, p = 0.890), need for ICU admission (1.8% vs. 3.7%, p = 0.683), or in-hospital mortality (0 vs. 1.8%, p = 0.342). Conclusions: The lower AP diagnoses indicate delayed and likely missed diagnoses, probably because of both hesitancy and organizational problems during the pandemic. The unchanged proportion of idiopathic forms supports the hypothesis that SARS-CoV-2 is not an AP trigger.
- 8 November 2023
- Published by MDPI AG in Gastroenterology Insights
- Vol. 14 (4) , 553-563
Open AccessCOVID-19 and Acute Pancreatitis: Not Increased Risk but Reduced Care
Background and aim: Over the last few years, SARS-CoV-2 has been reported as a possible cause of acute pancreatitis (AP), but whether it is a relevant clinical–epidemiological entity is still a matter of debate. We aim to evaluate the epidemiological characteristics of AP during the first year of the COVID pandemic (2020) and compare them with the pre-COVID period (2008–2019) to identify any differences and clarify a potential causative role of SARS-CoV-2. Methods: We used a monocentric retrospective study of 132 AP patients during 2020 and 1987 AP patients during 2008–2019. Diagnosis and severity were classified according to the revised Atlanta criteria. Propensity score matching was performed according to clinical–epidemiological features, and outcome analysis was performed on two subgroups of 109 patients. Results: The total number of AP cases in 2020 is one of the lowest in the last 13 years (132 cases, median 161, IQR 146-183). No major epidemiological differences were noted. During 2020, we observed a significant modification of the distribution of etiologies (p < 0.001), mainly based on a decrease in biliary forms (59.6% vs. 43.2%) and an increase in alcoholic forms (6.9% vs. 12.9%). Idiopathic forms remain unchanged (20.5% vs. 21.9%). The proportion of AP of idiopathic etiology and SARS-CoV-2 infection was 0.008%. There were no differences in terms of severity distribution (p = 0.127), length of stay (p = 0.916), need for ICU (p = 0.139), or mortality (p = 0.462). Even among statistically matched groups, there were no differences between the length of stay (9 vs. 10 days, p = 0.890), need for ICU admission (1.8% vs. 3.7%, p = 0.683), or in-hospital mortality (0 vs. 1.8%, p = 0.342). Conclusions: The lower AP diagnoses indicate delayed and likely missed diagnoses, probably because of both hesitancy and organizational problems during the pandemic. The unchanged proportion of idiopathic forms supports the hypothesis that SARS-CoV-2 is not an AP trigger.